Wilmington, DE, United States of America

Karl Plössl


Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2001-2019

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **The Innovative Contributions of Karl Plössl in Theranostic Agents**

Introduction

Karl Plössl is a notable inventor based in Wilmington, Delaware. He holds a patent that significantly impacts the field of medical imaging and therapeutics. His work on HBED-bisphosphonates and their application as theranostic agents showcases his commitment to advancing healthcare solutions.

Latest Patents

The patent held by Karl Plössl, titled "HBED-bisphosphonates, radiometal conjugates and their use as theranostic agents," introduces novel compounds according to Formula I and Formula II. These compounds have shown potential as bone imaging agents, particularly those labeled with gallium (Ga), which exhibit excellent bone uptake and retention. The invention also relates to pharmaceutical compositions that incorporate these compounds or their pharmaceutically acceptable salts.

Career Highlights

Karl Plössl is associated with Five Eleven Pharma Inc., where he continues to explore innovations in therapeutic agents. His work is at the intersection of chemistry and medicine, aiming to improve diagnostic and therapeutic methodologies in healthcare.

Collaborations

Throughout his career, Karl has collaborated with esteemed colleagues such as Hank F Kung and Zehui Wu. Their joint efforts have contributed to the progress of innovative treatments and compounds in the pharmaceutical industry, solidifying their roles as leaders in their field.

Conclusion

Karl Plössl's contributions to the development of HBED-bisphosphonates highlight the importance of innovation in the medical sector. His research not only enhances imaging techniques but also paves the way for new therapeutic options, ultimately benefiting patients and advancing the field of pharmacology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…